GenVec/Parke-Davis BioByPass set to enter clinicals in early 1998; companies sign $100 mil. R&D agreement.
GENVEC/PARKE-DAVIS BIOBYPASS TO BEGIN CLINICALS IN FIRST QUARTER 1998 in the initial indication of coronary artery disease. Patients in the trial will receive a one-time injection to the left ventricle of the gene therapy product, which delivers the vascular endothelial growth factor gene via an adenovirus vector. GenVec licenses the VEGF gene from Scios. A second study in peripheral vascular disease with BioByPass will follow soon after the first study.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth